Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.
Title: Identifying Predictive Plasma Proteomic Biomarkers for Clinical™ Response to AXA1125: An Endogenous Metabolic Modulator (EMM) Composition Being Developed for the Treatment of NAFLD/NASH
Session Type: Poster Session #2000 – 2999
Abstract Number: 2511
Date and Time: Saturday, November 5, 2022, 1:00 PM – 2:00 PM (ET)
Please come visit members of the Axcella team at Booth #444.
With 8,000 attendees The Liver Meeting is the world’s premier meeting on liver disease. Over the course of 5 days clinicians and scientists from around the world exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology. Attendees include:
- Adult and pediatric hepatology experts
- Clinical, basic, and translational researchers
- Specialists who diagnose and treat liver disease, including gastroenterologists, surgeons, clinical pathologists, anesthesiologists, and radiologists
- Primary care physicians
- Nurse practitioners, registered nurses, physician assistants, pharmacists, and other allied health professionals in hepatology and the disciplines listed above
- Patient advocates and patients
Internet Posting of Information
Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About Axcella Therapeutics (Nasdaq: AXLA)
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID, NASH, and the reduction in risk of OHE recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.